intermediatepharmacogenomicsHLA-B*1502carbamazepineStevens-Johnson syndrometoxic epidermal necrolysisFDA black box warning
A 32-year-old woman of Han Chinese ancestry presents with bipolar II disorder. After careful evaluation, the PMHNP is considering carbamazepine as a mood stabilizer given the patient's prior intolerance to lithium and valproate. Before initiating treatment, pharmacogenomic testing is ordered. The results reveal the patient is positive for the HLA-B*1502 allele. The PMHNP discusses the clinical significance of this finding with the patient. Which of the following best describes the pharmacogenomic rationale for testing HLA-B*1502 before prescribing carbamazepine?